Sun Pharma and Ranbaxy Synergy

Abstract

In 30 years of its existence, Sun Pharma has become one of the world's most profitable pharmaceuticals manufacturers. Sun Pharma has complemented its growth by way of extensive acquisitions and joint ventures in India and abroad. In addition to its formulations in various therapeutic areas, Sun Pharma also manufactures APIs to facilitate the manufacture of complex formulations such as anti-cancers, peptides. Ranbaxy is an Indian company listed on the BSE, NSE and the Luxembourg stock exchange, with ground operations in 43 countries and 21 manufacturing facilities spread across 8 countries. It is engaged in development, manufacturing and marketing of pharmaceutical products and APIs. The merger will improve Sun Pharma's global footprint in emerging pharma markets like Russia, Romania, Brazil, Malaysia and South Africa, offering opportunities for cross-selling and better brand-building. The merged entity will have combined pro-forma revenues of US$ 0.9 billion for CY 2013 in emerging pharma markets.